The PEN2–ATP6AP1 axis offers potential targets for screening for substitutes for metformin, which may be available to a wider range of tissues, such as muscle, thereby engendering better efficacy in treating diabetes and other metabolic diseases. Here, PSENEN is linked to metabolic disease.